C-IAP2在肝细胞肝癌中的表达及与临床预后的关系

目的探讨C-IAP2 mRNA和蛋白在肝细胞癌中的表达及其与临床预后的关系。方法采用荧光定量PCR和免疫组化方
法检测肝细胞癌组织及对应的非癌组织中C-IAP2 mRNA和蛋白的表达水平并分析肝癌组织中C-IAP2的表达和临床病理特征
之间的关系。结果肝细胞肝癌中C-IAP2 mRNA的表达是非癌组织的2.70倍（P<0.001）。C-IAP2蛋白在肝癌组织阳性表达率
为70.8%，显著高于非癌组织中的阳性表达率27.8%（P=0.001）。C-IAP2 mRNA和蛋白在肝癌组织中的表达与术前有无癌栓、
有无淋巴结转移、甲胎蛋白水平、肿瘤病理分化类型、TNM分期以及术后复发转移时间有关（P<0.05），而与患者性别、年龄、乙型
肝炎表面抗原、肿瘤大小、肿瘤数目、肝硬化以及包膜完整性无关（P>0.05）。结论C-IAP2表达水平与原发性肝癌的转移、复发
有关，可作为原发性肝细胞癌预后的新生物学指标。

Association of cellular inhibitor of apoptosis protein-2 expression with clinical outcomes of hepatocellular carcinoma

Objective To study the expression of cellular inhibitor of apoptosis protein-2(C-IAP2) mRNA and protein in hepatocellular carcinoma(HCC) and its relationship with the clinical outcomes.Methods Quantitative PCR and immunohistochemical staining were used to detect the expression of C-IAP2 mRNA and protein in the tumor tissues and corresponding adjacent non-cancerous tissues from HCC patients.Results The expression of C-IAP2 mRNA in HCC tissues was 2.70 folds higher than that in the non-cancerous tissues(P<0.001).The expression rate of C-IAP2 protein in HCC tissues was 70.8%,significantly higher than that in the non-cancerous tissues(27.8%,P=0.001).The expression of C-IAP2 mRNA and protein was associated with the tumor emboli,lymph node metastasis,AFP level,histological differentiation,TNM stage,postoperative recurrence and metastasis(P<0.05),but not with the patients’ gender,age,HbsAg positivity,number of tumors,cirrhosis or the presence of tumor encapsulation(P>0.05).Conclusion The expression of C-IAP2 in HCC is associated with tumor recurrence and metastasis,and can be a biological marker for prognostic evaluation of HCC.